Northwest Biotherapeutics secures $5.505M, 22‑month loan

Northwest Biotherapeutics (NWBO) entered into a $5,505,000 commercial loan with Streeterville Capital, LLC.

Rhea-AI Filing Summary

Northwest Biotherapeutics (NWBO) entered into a $5,505,000 commercial loan with Streeterville Capital, LLC. The loan has a 22‑month term, bears 8% annual interest, and includes a 10% original issue discount. There are no repayments for the first eight months, with repayments beginning on June 26, 2026.

After repayments begin, the note amortizes over 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. The company may prepay at its election, subject to a 10% prepayment charge, and the agreement contains customary default and acceleration provisions. Proceeds will support ongoing business operations.

Insights

Credit analyst

$5.505M loan adds liquidity; terms include 8% rate and OID.

NWBO secured a $5,505,000 loan from Streeterville with a 8% annual interest rate and a 10% original issue discount. The structure defers cash outflow for eight months, then shifts to scheduled amortization.

Beginning June 26, 2026, principal amortizes over 14 equal monthly installments at 110% of the pro rata principal amount, plus accrued interest. Prepayment is permitted but carries a 10% charge, and customary default terms allow potential acceleration.

Near term, this provides operating cash for ongoing activities. Actual cash cost reflects interest, the OID, and the prepayment premium if used. Key milestones are the first payment on June 26, 2026 and completion of the 14‑month amortization thereafter.

8-K Event Classification

2 items: 1.01, 2.03

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did NWBO announce in the 8-K?

NWBO entered into a $5,505,000 commercial loan with Streeterville Capital, LLC.

What are the key terms of NWBO’s new loan?

The loan has a 22‑month term, 8% annual interest, and a 10% original issue discount.

When do repayments on NWBO’s loan begin?

There are no repayments for the first eight months; repayments begin on June 26, 2026.

How is the NWBO loan repaid after the deferral period?

It amortizes in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest.

Can NWBO prepay the loan, and is there a penalty?

Yes. The company may prepay at any time, with a 10% prepayment charge.

What will NWBO use the loan proceeds for?

The funds will be used for ongoing business operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 12:29 PM Learn about SEC filing dates

false 0001072379 0001072379 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 27, 2025

Northwest Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-35737		94-3306718
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

(Address of Principal Executive Offices)

(240) 497-9024

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, par value, $0.001 per share		NWBO		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

Loan Entered Into

On October 27, 2025, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $5,505,000. The Loan Agreement has a maturity of 22 months. There are no repayments for the first 8 months. Repayments will begin June 26, 2026.

Following June 26, 2026, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.

The funds will be used for the Company’s ongoing business operations.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC.
Date: October 31, 2025	By:	/s/ Linda Powers
	Name:	Linda Powers
	Title:	Chief Executive Officer and Chairman